Aim: The aim of this study is to study the levels of cancer antigen 125 (CA-125) in normal, preeclampsia, and gestational hypertension study groups and correlate with other parameters which mark the severity of the disease. Materials and methods: A cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. A total of 165 subjects were divided into three study groups: preeclampsia, gestational hypertension, and normal pregnancy, and each group consisted of 55 subjects. CA-125 levels were measured in these study groups. Results: The mean value of CA-125 in the preeclampsia group was 56.7 IU/mL which was significantly higher compared with other two study groups. CA-125 was found to have a positive correlation with systolic blood pressure (BP) (r value = 0.4, p value = 0.001), diastolic BP (r value = 0.3, p value = 0.001), and uric acid (r value = 0.2, p value = 0.001) and also an association was observed between increasing CA-125 and proteinuria (p value = 0.001) oligohydramnios (p value = 0.001) fetal growth restriction (p value = 0.03) and onset of the disease (p value = 0.001). However, a negative correlation with platelets (r value = −0.14, p value = 0.06) and birth weight (r value = −0.113, p value = 0.15) was observed. Conclusion: CA-125 is a marker indicating increasing severity of the disease. It is a biochemical marker which can be used in the screening of preeclampsia. Further studies are needed for the evaluation of raising serial CA-125 levels as a marker of progression of the disease. Clinical significance: Hypertensive disorders of pregnancy are one of the most common causes of death due to pregnancy. CA-125 was proposed to be elevated in patients with hypertension due to chronic inflammation. Hence, CA-125 levels if used as a screening tool can estimate the severity of the disease and help clinicians in identifying women who are at risk for further complications and act accordingly.
All Science Journal Classification (ASJC) codes
- Obstetrics and Gynaecology